Total trials
1,848
Active
339
Phase 3
214
Total enrollment
179,600
Pipeline matrix
Showing 40 of 208 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dexmedetomidine | 41 | ||||||
| Bupivacaine | — | — | 18 | ||||
| Zinc | — | — | — | — | 3 | ||
| Tamsulosin | — | — | — | 3 | |||
| Triamcinolone Acetonide | — | — | — | — | 3 | ||
| Hydrocortisone | — | — | — | — | — | 3 | |
| Dentin Graft | — | — | — | — | — | 1 | |
| Piracetam | — | — | — | — | — | 1 | |
| Caffeine | — | — | — | — | — | 1 | |
| triptans | — | — | — | — | — | 1 | |
| NSAID | — | — | — | — | — | 1 | |
| Propofol + fentanyl + Atracurium | — | — | — | — | — | 1 | |
| Isoflurane and Atracurium | — | — | — | — | — | 1 | |
| Ursodeoxycholic Acid 250 Mg Oral | — | — | — | — | — | 1 | |
| Probiotic Formula | — | — | — | — | — | 1 | |
| Nicotinamide 1000 mg | — | — | — | — | — | 1 | |
| ferric hydroxide polymaltose complex | — | — | — | — | — | 1 | |
| Albendazole. | — | — | — | — | — | 1 | |
| Erythropoietin carried on chitosan carrier | — | — | — | — | — | 1 | |
| Low-concentration carbohydrate and nitrates | — | — | — | — | — | 1 | |
| Low-concentration carbohydrate | — | — | — | — | — | 1 | |
| Erythropoetin gel mixed with xenogenic bone graft | — | — | — | — | — | 1 | |
| Itopride HCI 50 mg | — | — | — | — | — | 1 | |
| Ketodex | — | — | — | — | — | 1 | |
| Labetalol | — | — | — | — | — | 1 | |
| bupivacaine 0.25 % | — | — | — | — | — | 1 | |
| Silodosin | — | — | — | — | — | 1 | |
| Calcium Hydroxide | — | — | — | — | — | 1 | |
| PPI | — | — | — | — | — | 1 | |
| Probiotic | — | — | — | — | — | 1 | |
| N Acetyl cysteine, 1200mg | — | — | — | — | — | 1 | |
| paracetamol | — | — | 6 | ||||
| chitosan nanoparticles gel | — | — | — | — | 2 | ||
| Alpha lipoic acid | — | — | — | — | 4 | ||
| control group | — | — | — | — | 3 | ||
| Melatonin | — | — | 7 | ||||
| Alpha Lipoic Acid 600 MG Oral | — | — | — | — | 4 | ||
| Lactoferrin | — | — | — | 4 | |||
| n acetyl cysteine | — | — | — | 3 | |||
| Glutamine | — | — | — | — | — | 2 |
168 more active programs hidden
Next readouts
- 2024-06-24
- 2024-09-01
- 2024-10-31
- 2024-12-04
- 2024-12-31
- 2024-12-31
- 2025-01
- 2025-01-01
- 2025-02
- 2025-02-28
Top conditions
- Anesthesia53
- Postoperative Pain27
- Post Operative Pain27
- Sepsis19
- Periodontitis15
- Analgesia13
- Breast Cancer13
- Covid1912
Frequently asked questions about Ain Shams University
- How many clinical trials does Ain Shams University have on ClinicalTrials.gov?
- Ain Shams University is listed as the lead sponsor on 1,848 clinical trials in ClinicalTrials.gov, 339 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Ain Shams University's trials are in Phase 3?
- 214 of Ain Shams University's trials are in Phase 3, spread across 208 active drug programs.
- What therapeutic areas does Ain Shams University focus on?
- Ain Shams University's most-studied conditions on ClinicalTrials.gov are Anesthesia, Postoperative Pain, Post Operative Pain, Sepsis, Periodontitis.
- When are Ain Shams University's next clinical trial readouts?
- Ain Shams University has 10 upcoming primary-completion readouts tracked here; the soonest is “Evaluation of Locally Delivered Propolis Gels in Periodontitis”, expected around 2024-06-24.